AMOYTOP(SH:688278) 智通财经网·2025-10-12 08:26Core Viewpoint - The company Teva Biopharmaceuticals (688278.SH) has received approval from the National Medical Products Administration for the marketing application of its product Pegbinterferon, which is now indicated for the sustained clearance of HBsAg in adult patients with chronic hepatitis B [1] Group 1: Product Information - Pegbinterferon is the company's core product and is the world's first 40kD polyethylene glycol long-acting interferon α-2b injection [1] - It is classified as a Category 1 new drug for biological products in China and is the first domestically marketed PEG-modified interferon in the country [1] - Pegbinterferon was approved for marketing in October 2016 for the treatment of adult chronic hepatitis C and received approval for the indication of adult chronic hepatitis B in September 2017 [1]